Dr. Erika Kancler
Objective: To evaluate the overall efficacy, advantages, and disadvantages of treatment with direct factor Xa inhibitors as compared to warfarin in the prevention of stroke in patients with atrial fibrillation. Methods: A quantitative meta-analysis was performed on three separate studies, each of which evaluated the efficacy and safety outcomes of a direct factor Xa inhibitor versus warfarin in preventing stroke in patients with atrial fibrillation. The direct factor Xa inhibitors that were evaluated included apixaban, edoxaban, and rivaroxaban. Results: The direct factor Xa inhibitors were found to be as effective, and in some cases more effective, than warfarin in preventing stroke in patients with atrial fibrillation. In addition, the direct factor Xa inhibitors were associated with a significantly decreased rate of major bleeding events, as compared to warfarin.
Lof A, Pillai S. Comparing direct factor Xa inhibitors and warfarin in the prevention of stroke in patients with atrial fibrillation. JMU Scholarly Commons Physician Assistant Capstones. http://commons.lib.jmu.edu/pacapstones/12/. Published August 1, 2016.